4CPS-110 Impact of patients’ conditions on the effectiveness and safety of erlotinib in pancreatic cancer

BackgroundIn post-PA studies in the use of erlotoinib, it was observed that the favourable clinical situation benefited the response to treatment.PurposeTo compare the effectiveness and safety of erlotinib, according to the Eastern Cooperative Oncology Group (ECOG), in pancreatic cancer.Material and...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2018-03, Vol.25 (Suppl 1), p.A93-A93
Main Authors: García, I Muñoz, Martínez-Penella, M, Mira-Sirvent, MC, Núñez-Bracamonte, S, Conesa-Nicolás, E, Viney, AC, Juez-Santamaria, C, Lloret-Llorca, A, García-Márquez, A, García-Lagunar, MH, Gutiérrez-Cívicos, MDR
Format: Article
Language:English
Subjects:
Metastasis
Pancreatic cancer
Section 4: Clinical pharmacy services
Targeted cancer therapy
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundIn post-PA studies in the use of erlotoinib, it was observed that the favourable clinical situation benefited the response to treatment.PurposeTo compare the effectiveness and safety of erlotinib, according to the Eastern Cooperative Oncology Group (ECOG), in pancreatic cancer.Material and methodsRetrospective observational study with pancreatic cancer patients treated with erlotinib, in a third-level care hospital from January 2009 to March 2017. A database was developed with demographic, clinical (Selene®) and pharmacotherapeutic data (Savac®). The data were analysed with SPSS® (version23). The level of statistical significance was p≤0.05.ResultsWe obtained 34 patients, excluding one patient due to insufficiente clinical data. The remaining 33 patients: 57.58% males with a median age of 60.8 years (IQR :54–67). Eighteen patients (54.55%) were smokers. In 28 patients (84.85%), the disease was metastatic and and in five, locally advanced. Erlotinib was used in 15 patients such as the first line (with gemcitabine in 14 of them). Erlotinib in the second line was used in 11 (nine with gemcitabine and one with capecitabine) and seven in the third line (six with gemcitabine).The median progression-free survival (PFS) of the 33 patients was 2.4 months (RI: 1.57–5) and the median overall survival (OS) was 6 months (RI: 2.17–12.17).Subgroup analysis according to ECOG at the start of treatment: characteristics were: a) ECOG
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2018-eahpconf.201